Preliminary Trial of SNA014 for Pancreatic Cancer

May 13, 2026 updated by: SmartNuclide Biopharma

A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

12

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300000
        • Recruiting
        • Tianjin Medical University Cancer Institute and Hospital
        • Contact:
          • Tianjin Medical University Cancer Institute and Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Aged between 18 and 75 years (inclusive);
  2. Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
  3. Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
  4. Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
  5. Pathology test results from within the past year;

Exclusion Criteria:

  1. Patients with other clearly diagnosed malignant tumours;
  2. Patients with uncontrolled severe infections, or those with other serious comorbidities;
  3. Patients with a life expectancy of ≤3 months;
  4. Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
  5. Patients deemed unsuitable for participation in this study by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group
68Ga-NODAGA-SNA006
Drug: 68Ga-NODAGA-SNA006
Administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The safety and tolerability profile of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
Time Frame: 1 week
Occurrence of AE/SAE according to CTCAE 5.0
1 week
CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
Time Frame: 1 week
SUVmax of tumors
1 week
CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
Time Frame: 1 week
SUVmean of tumors
1 week
CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
Time Frame: 1 week
Correlation of tumor uptakes and Immunohistochemistry
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SmartNuclide Biopharma

Collaborators

Tianjin Medical University Cancer Institute and Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

April 21, 2026

First Submitted That Met QC Criteria

May 13, 2026

First Posted (Actual)

May 19, 2026

Study Record Updates

Last Update Posted (Actual)

May 19, 2026

Last Update Submitted That Met QC Criteria

May 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SNA014-202501

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Cancer

Clinical Trials on 68Ga-NODAGA-SNA006

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe